This endorsement marks a critical milestone in expanding access to the therapy, which was developed through a strategic research alliance between Sweden’s BioArctic AB and its partner, Eisai. While the recommendation is a major step forward, the drug is not yet available through public provincial plans. The process now shifts to negotiations via the pan-Canadian Pharmaceutical Alliance to determine pricing and coverage frameworks before individual provinces and territories make their final reimbursement decisions.

The timing of this approval is particularly relevant given the shifting landscape of dementia care in the country. Current estimates from 2025 indicate that over 770,000 Canadians are living with dementia, a figure projected to more than double to 1.7 million by 2050. Leqembi, a humanized monoclonal antibody, works by targeting amyloid-beta to slow disease progression. With this latest regulatory nod, Canada joins a growing list of nations integrating the treatment into their healthcare systems, following approvals in 53 other countries.